Immunic (IMUX) Cash & Equivalents (2013 - 2026)

Immunic has disclosed Cash & Equivalents across 14 years of filings, most recently posting $186.6 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $186.6 million, up 1204.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $186.6 million (up 1204.73% YoY), and the FY2025 annual result was $15.5 million, down 56.59% from the prior year.
• Cash & Equivalents came in at $186.6 million for Q1 2026 at Immunic, up from $15.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $186.6 million in Q1 2026 to a low of $14.3 million in Q1 2025.
• The 5-year median for Cash & Equivalents is $72.8 million (2022), against an average of $71.7 million.
• Across the five-year window, Cash & Equivalents tumbled 85.3% in 2025 and soared 1204.73% in 2026, its largest moves.
• Immunic's Cash & Equivalents stood at $106.7 million in 2022, then tumbled by 56.28% to $46.7 million in 2023, then slipped by 23.58% to $35.7 million in 2024, then plunged by 56.59% to $15.5 million in 2025, then jumped by 1105.38% to $186.6 million in 2026.
• The last three Cash & Equivalents figures came in at $186.6 million (Q1 2026), $15.5 million (Q4 2025), and $35.1 million (Q3 2025), per Business Quant data.